OncoNano Medicine, Inc.
About OncoNano Medicine, Inc.
OncoNano Medicine, Inc. is a Dallas, Texas-based biotechnology company and spinoff from UT Southwestern Medical Center that develops pH-responsive fluorescent nanoprobes and polymeric micelle platforms for real-time tumor visualization during surgery and targeted cancer therapeutics. Its lead imaging agent, pegsitacianine (TT1-L1N3), exploits acidic tumor microenvironments to glow under near-infrared light, improving resection accuracy in preclinical models of breast and pancreatic cancers. The company also advances ONM-501, a STING agonist therapeutic, and the ON-BOARD delivery platform for precise payload delivery to tumors. It operates as a privately held B2B entity focused on product sales in the medical devices and biotechnology sectors.
- 🔗 Onconano Medicine Funding, Investors & Competitors | Multiples
- 🔗 OncoNano Medicine, Inc. Company Overview, Contact Details & Competitors | LeadIQ
- 🔗 $18.4 Million Equity Investment by the Cancer Prevention and Research Institute of Texas — OncoNano
- 🔗 OncoNano Medicine Raises ~$50 Million in Series B Financing — OncoNano
- 🔗 OncoNano Medicine 2026 Company Profile: Valuation, Funding & Investors | PitchBook
Key highlights
- Raised ~$50M Series B led by Advantech Capital to advance pegsitacianine and ONM-501.
- CPRIT converted $18.4M in grants into equity investment in 2021 for clinical development.
- Developing pH-responsive nanoprobes that improve tumor margin visualization in surgery.
- Entered research collaboration with Gilead using ON-BOARD platform for drug delivery.
- Total funding reached ~$188M across 7 rounds including grants and equity.
Ask StreetZero about OncoNano Medicine, Inc.
Put our AI to work on this deal.
Similar companies
Other Biotechnology deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account